Media Conference
The Latest Media Conference
Information Meeting on FY 2018.12 Financial Results
Date:
January 31, 2019
Presentations:
- New Mid-term Business Plan “IBI 21”
- Tatsuro Kosaka,
President and CEO - FY2018 Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
Materials:
2018
-
November 07, 2018
- Information Meeting on GAZYVA®
-
- 1. Product Overview of GAZYVA® Intravenous Infusion 1000 mg
- Naoko Oya, GAZYVA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. Pathology of Follicular Lymphoma and Clinical Trial Results of obinutuzumab
- Kiyohiko Hatake, M.D., Ph.D.
Deputy Director, Head of the Malignant Tumor and Hematologic Tumor Center at the International University of Health and Welfare, Mita Hospital, Japan
-
October 24, 2018
- 3Q Results (Jan - Sep 2018) Conference Call
-
- FY2018 3Q Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President & CFO - Overview of Development Pipeline
- Dr. Minoru Hirose,
Department Manager of R&D Portfolio Management Dept.,
Project & Lifecycle Management Unit
-
July 26, 2018
- Media Conference on FY2018 2Q Financial Results
-
- Aiming to Achieve Mid-term Business Plan “IBI 18”
- FY2018 Half Year Results - - Tatsuro Kosaka,
President and CEO - FY2018 2Q Consolidated Financial Overview (IFRS based)
- Toshiaki Itagaki,
Executive Vice President and CFO - Overview of Development Pipeline
- Dr. Yasushi Ito,
Executive Vice President and Co-Head of Project & Lifecycle Management Unit
- Aiming to Achieve Mid-term Business Plan “IBI 18”
-
Jun 01, 2018
- Information Meeting on HEMLIBRA®
-
- 1. HEMLIBRA® Subcutaneous Injection Product Overview
- Hiroshi Motegi, HEMLIBRA® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. Current Status of Hemophilia Treatment and Expectations for HEMLIBRA®
- Prof. Midori Shima, M.D., Ph.D.
Department of Pediatrics, Nara Medical University
-
Apr 12, 2018
- Information Meeting on TECENTRIQ®
-
- 1. TECENTRIQ® Intravenous Infusion 1200mg Product Overview
- Mikio Sakai, TECENTRIQ® Lifecycle Leader, Chugai Pharmaceutical Co., Ltd.
- 2. The Anti-PD-L1 Antibody Tecentriq® Mode of Action and Future Outlook
- Hiroyoshi Nishikawa, M.D., Ph.D.
Department of Immunology, Nagoya University Graduate School of Medicine
Exploratory Oncology Research & Clinical Trial Center, Research Institute, National Cancer Center - 3. Treatment Overview of Non-Small Cell Lung Cancer and Clinical Trials for Tecentriq®
- Yuichiro Ohe, M.D.
Deputy Director, Chief,
Division of Thoracic Oncology
National Cancer Center Hospital, Japan
-
Feb 01, 2018
- Media Conference on 2017.12 Financial Results
-
- Aiming to Achieve Mid-Term Business Plan “IBI 18”
-2017 Results and 2018 Outlook- - Tatsuro Kosaka, President, COO
- FY2017 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit
- Aiming to Achieve Mid-Term Business Plan “IBI 18”
2017
-
Oct 30, 2017
- CEO Meeting
-
- Drastic Changes in the Environment of the New Drug Creation and Challenges Facing Japan’s Pharmaceutical Industry
- Chairman and CEO Osamu Nagayama
-
Jul 27, 2017
- Media Conference on FY2017 2Q Financial Results
-
- FY2017 2Q Consolidated Financial Overview
- Yoshio Itaya,
Executive Vice President, CFO - Overview of Development Pipeline
- Yasushi Ito,
Senior Vice President, Head of Project & Lifecycle Management Unit
-
Feb 01, 2017
- Media Conference on 2016.12 Financial Results
-
- Mid-Term Business Plan “IBI 18”
-2016 Results and 2017 Outlook- - Tatsuro Kosaka, President, COO
- FY2016 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yasushi Ito, Senior Vice President,
Head of Project & Lifecycle Management Unit - Reorganization to Provide a New Solution
- Susumu Kato, Senior Vice President,
General Manager of Marketing & Sales Div.
- Mid-Term Business Plan “IBI 18”
2016
-
Jul 21, 2016
- Media Conference on FY2016 2Q Financial Results
-
- FY2016 2Q Consolidated Financial Overview
- Yoshio Itaya,
Executive Vice President CFO - Overview of Development Pipeline
- Minoru Watanabe,
Associate Vice President
Deputy General Manager of Research Division
-
May 19, 2016
- Joint Press Conference by Osaka University and Chugai Pharmaceutical Co., Ltd.
-
- Outline of the Comprehensive Collaboration Agreement between Osaka University and Chugai Pharmaceutical Co., Ltd.
- Executive Vice President of Research and Risk Management, Osaka University
Yasushi Yagi - Outline of Comprehensive Collaboration with IFReC
- CHUGAI PHARMACEUTICAL CO., LTD.
Executive Vice President
Yutaka Tanaka
-
Apr 05, 2016
- Information Meeting on Bonviva®
-
- 1. Product Overview of Bonviva® Tablet
- Takeshi Sakaguchi
Bonviva® Product Manager
Chugai Pharmaceutical Co., Ltd. - 2. Bonviva® Tablet: Clinical Utility and Our Expectation
- Hiroshi Hagino, M.D., Ph.D., Professor
School of Health Science
Tottori University Faculty of Medicine, Japan
- Presentation [PDF 3.2MB]
- Webcast(END)
-
Jan 28, 2016
- Media Conference on 2015.12 Financial Results
-
- New Mid-Term Business Plan "IBI 18"
- Tatsuro Kosaka, President, COO
- FY2015 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President
2015
-
Jul 23, 2015
- Media Conference on FY 2015.12 2Q Financial Results
-
- FY2015 2Q Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President
-
Apr 02, 2015
- Information Meeting on ZELBORAF®
-
- 1. Overview of ZELBORAF®
- Takahiro Mizui
ZELBORAF® Lifecycle Leader
CHUGAI PHARMACEUTICAL CO., LTD. - 2. cobas® BRAF V600 Mutation Test
- Toru Ogawa
Manager, Molecular Diagnostics
Roche Diagnostics K.K. - 3. ZELBORAF® tablet Postmarketing safety measures
- Shin Yoshida
Pharmacovigilance Department
CHUGAI PHARMACEUTICAL CO., LTD. - 4．Overview of melanoma and clinical trials of vemurafenib
- Naoya Yamazaki, M.D., Ph.D.
Chief, Dept. of Dermatologic Oncology
National Cancer Center Hospital, Japan
- Presentation [PDF 2.2MB]
- Webcast(END)
-
Jan 28, 2015
- Media Conference on 2014.12 Financial Results
-
- Aiming to Become a Top Pharmaceutical Company
- Tatsuro Kosaka, President, COO
- FY2014 Consolidated Financial Overview
- Yoshio Itaya, Executive Vice President, CFO
- Overview of Development Pipeline
- Yutaka Tanaka, Executive Vice President,
Head of Project & Lifecycle Management Unit
